New antibody drug for blood cancer tested – but trial never started
NCT ID NCT05263739
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 24 times
Summary
This early-stage trial was designed to test the safety and best dose of a new drug called ESG206 in adults with advanced B-cell blood cancers that had stopped responding to standard treatments. The drug works by targeting a protein on cancer cells to help the immune system attack them. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOID MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.